- Home
- EYEN vs LIPO Comparison
EYEN vs LIPO Comparison
Compare EYEN & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- LIPO
- Stock Information
- Founded
- EYEN 2014
- LIPO 2005
- Country
- EYEN United States
- LIPO United States
- Employees
- EYEN N/A
- LIPO N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- LIPO Health Care
- Exchange
- EYEN Nasdaq
- LIPO Nasdaq
- Market Cap
- EYEN 2.9M
- LIPO 3.1M
- IPO Year
- EYEN 2018
- LIPO 2022
- Fundamental
- Price
- EYEN $4.88
- LIPO $2.99
- Analyst Decision
- EYEN Hold
- LIPO
- Analyst Count
- EYEN 4
- LIPO 0
- Target Price
- EYEN $2.00
- LIPO N/A
- AVG Volume (30 Days)
- EYEN 7.1M
- LIPO 39.2K
- Earning Date
- EYEN 05-19-2025
- LIPO 05-14-2025
- Dividend Yield
- EYEN N/A
- LIPO N/A
- EPS Growth
- EYEN N/A
- LIPO N/A
- EPS
- EYEN N/A
- LIPO N/A
- Revenue
- EYEN $67,063.00
- LIPO $519,866.00
- Revenue This Year
- EYEN $7,680.45
- LIPO N/A
- Revenue Next Year
- EYEN $315.38
- LIPO N/A
- P/E Ratio
- EYEN N/A
- LIPO N/A
- Revenue Growth
- EYEN 663.82
- LIPO 8.88
- 52 Week Low
- EYEN $0.85
- LIPO $1.97
- 52 Week High
- EYEN $124.80
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- EYEN 86.35
- LIPO 58.50
- Support Level
- EYEN $1.62
- LIPO $2.75
- Resistance Level
- EYEN $2.30
- LIPO $3.17
- Average True Range (ATR)
- EYEN 0.53
- LIPO 0.29
- MACD
- EYEN 0.27
- LIPO 0.02
- Stochastic Oscillator
- EYEN 79.17
- LIPO 81.05
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.